Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant hyperthermia].

Fritz Zimprich1, Hans Georg Kress, Josef Zeitlhofer

  • 1Universitätsklinik für Neurologie, Wien, Osterreich.

Wiener Klinische Wochenschrift
|October 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Delphi consensus on integrating novel therapies into the management of generalized myasthenia gravis.

Therapeutic advances in neurological disorders·2026
Same author

Hereditary Transthyretin Amyloidosis in Austria: Clinical, Genetic, and Demographic Insights from a Nationwide Cohort.

Journal of clinical medicine·2026
Same author

Diagnostic performance and safety of the edrophonium test in myasthenia gravis: a retrospective case-control study.

Neurological research and practice·2026
Same author

Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria.

Journal of neurology·2026
Same author

Efficacy and safety of risdiplam in adults with 5q-associated spinal muscular atrophy: a nationwide observational cohort study in Austria.

EClinicalMedicine·2025
Same author

Dermatomyositis masking late onset Pompe disease in a patient with proximal muscle weakness.

Journal of neuromuscular diseases·2025

Malignant hyperthermia (MH) is a severe muscle disorder triggered by anesthesia. Early diagnosis via the in vitro contracture test and dantrolene treatment have significantly reduced MH-related deaths.

Area of Science:

  • Genetics
  • Pharmacology
  • Neuromuscular Disorders

Background:

  • Malignant hyperthermia (MH) is an autosomal dominant skeletal muscle disorder.
  • It causes life-threatening hypermetabolic reactions to specific anesthetics and muscle relaxants.
  • Genetic defects, primarily in the ryanodine receptor gene, underlie MH.

Purpose of the Study:

  • To summarize the current understanding of malignant hyperthermia.
  • To highlight advancements in diagnostic and therapeutic approaches.
  • To emphasize the need for interdisciplinary collaboration in managing MH.

Main Methods:

  • Review of genetic defects in the ryanodine receptor gene.
  • Evaluation of the in vitro contracture test for MH diagnosis.

Related Experiment Videos

  • Assessment of dantrolene as an intravenous treatment for MH.

    • Main Results:

    • Significant reduction in mortality rates due to improved diagnostic and therapeutic tools.
    • Identification of genetic mutations in the sarcoplasmic reticulum ryanodine receptor.
    • Recognition of MH-like reactions in other neuromuscular disorders.

    Conclusions:

    • The in vitro contracture test and dantrolene treatment have dramatically decreased MH mortality.
    • Timely recognition of MH requires collaboration across clinical disciplines.
    • MH remains a life-threatening disorder necessitating ongoing vigilance and research.